306 related articles for article (PubMed ID: 25336650)
1. O-GlcNAcase: promiscuous hexosaminidase or key regulator of O-GlcNAc signaling?
Alonso J; Schimpl M; van Aalten DM
J Biol Chem; 2014 Dec; 289(50):34433-9. PubMed ID: 25336650
[TBL] [Abstract][Full Text] [Related]
2. Structural and functional insight into human O-GlcNAcase.
Roth C; Chan S; Offen WA; Hemsworth GR; Willems LI; King DT; Varghese V; Britton R; Vocadlo DJ; Davies GJ
Nat Chem Biol; 2017 Jun; 13(6):610-612. PubMed ID: 28346405
[TBL] [Abstract][Full Text] [Related]
3. Elucidating the protein substrate recognition of O-GlcNAc transferase (OGT) toward O-GlcNAcase (OGA) using a GlcNAc electrophilic probe.
Kositzke A; Fan D; Wang A; Li H; Worth M; Jiang J
Int J Biol Macromol; 2021 Feb; 169():51-59. PubMed ID: 33333092
[TBL] [Abstract][Full Text] [Related]
4. O-GlcNAc processing enzymes: catalytic mechanisms, substrate specificity, and enzyme regulation.
Vocadlo DJ
Curr Opin Chem Biol; 2012 Dec; 16(5-6):488-97. PubMed ID: 23146438
[TBL] [Abstract][Full Text] [Related]
5. Chemical and Biochemical Strategies To Explore the Substrate Recognition of O-GlcNAc-Cycling Enzymes.
Hu CW; Worth M; Li H; Jiang J
Chembiochem; 2019 Feb; 20(3):312-318. PubMed ID: 30199580
[TBL] [Abstract][Full Text] [Related]
6. Evidence of a compensatory regulation of colonic O-GlcNAc transferase and O-GlcNAcase expression in response to disruption of O-GlcNAc homeostasis.
Decourcelle A; Loison I; Baldini S; Leprince D; Dehennaut V
Biochem Biophys Res Commun; 2020 Jan; 521(1):125-130. PubMed ID: 31630803
[TBL] [Abstract][Full Text] [Related]
7. Changes in O-Linked N-Acetylglucosamine (O-GlcNAc) Homeostasis Activate the p53 Pathway in Ovarian Cancer Cells.
de Queiroz RM; Madan R; Chien J; Dias WB; Slawson C
J Biol Chem; 2016 Sep; 291(36):18897-914. PubMed ID: 27402830
[TBL] [Abstract][Full Text] [Related]
8. Identification of a specific inhibitor of nOGA - a caspase-3 cleaved O-GlcNAcase variant during apoptosis.
Li J; Li Z; Li T; Lin L; Zhang Y; Guo L; Xu Y; Zhao W; Wang P
Biochemistry (Mosc); 2012 Feb; 77(2):194-200. PubMed ID: 22348480
[TBL] [Abstract][Full Text] [Related]
9. Structural insights into the substrate binding adaptability and specificity of human O-GlcNAcase.
Li B; Li H; Hu CW; Jiang J
Nat Commun; 2017 Sep; 8(1):666. PubMed ID: 28939839
[TBL] [Abstract][Full Text] [Related]
10. Human OGA binds substrates in a conserved peptide recognition groove.
Schimpl M; Schüttelkopf AW; Borodkin VS; van Aalten DM
Biochem J; 2010 Nov; 432(1):1-7. PubMed ID: 20863279
[TBL] [Abstract][Full Text] [Related]
11. Distinctive inhibition of O-GlcNAcase isoforms by an alpha-GlcNAc thiolsulfonate.
Kim EJ; Amorelli B; Abdo M; Thomas CJ; Love DC; Knapp S; Hanover JA
J Am Chem Soc; 2007 Dec; 129(48):14854-5. PubMed ID: 17994748
[TBL] [Abstract][Full Text] [Related]
12. GlcNAcstatins are nanomolar inhibitors of human O-GlcNAcase inducing cellular hyper-O-GlcNAcylation.
Dorfmueller HC; Borodkin VS; Schimpl M; van Aalten DM
Biochem J; 2009 May; 420(2):221-7. PubMed ID: 19275764
[TBL] [Abstract][Full Text] [Related]
13. Genetic recoding to dissect the roles of site-specific protein O-GlcNAcylation.
Gorelik A; Bartual SG; Borodkin VS; Varghese J; Ferenbach AT; van Aalten DMF
Nat Struct Mol Biol; 2019 Nov; 26(11):1071-1077. PubMed ID: 31695185
[TBL] [Abstract][Full Text] [Related]
14. Structure of a bacterial putative acetyltransferase defines the fold of the human O-GlcNAcase C-terminal domain.
Rao FV; Schüttelkopf AW; Dorfmueller HC; Ferenbach AT; Navratilova I; van Aalten DM
Open Biol; 2013 Oct; 3(10):130021. PubMed ID: 24088714
[TBL] [Abstract][Full Text] [Related]
15. Insights into activity and inhibition from the crystal structure of human O-GlcNAcase.
Elsen NL; Patel SB; Ford RE; Hall DL; Hess F; Kandula H; Kornienko M; Reid J; Selnick H; Shipman JM; Sharma S; Lumb KJ; Soisson SM; Klein DJ
Nat Chem Biol; 2017 Jun; 13(6):613-615. PubMed ID: 28346407
[TBL] [Abstract][Full Text] [Related]
16. Defining the structural origin of the substrate sequence independence of O-GlcNAcase using a combination of molecular docking and dynamics simulation.
Martin JC; Fadda E; Ito K; Woods RJ
Glycobiology; 2014 Jan; 24(1):85-96. PubMed ID: 24134879
[TBL] [Abstract][Full Text] [Related]
17. Insights into O-linked N-acetylglucosamine ([0-9]O-GlcNAc) processing and dynamics through kinetic analysis of O-GlcNAc transferase and O-GlcNAcase activity on protein substrates.
Shen DL; Gloster TM; Yuzwa SA; Vocadlo DJ
J Biol Chem; 2012 May; 287(19):15395-408. PubMed ID: 22311971
[TBL] [Abstract][Full Text] [Related]
18. Caenorhabditis elegans ortholog of a diabetes susceptibility locus: oga-1 (O-GlcNAcase) knockout impacts O-GlcNAc cycling, metabolism, and dauer.
Forsythe ME; Love DC; Lazarus BD; Kim EJ; Prinz WA; Ashwell G; Krause MW; Hanover JA
Proc Natl Acad Sci U S A; 2006 Aug; 103(32):11952-7. PubMed ID: 16882729
[TBL] [Abstract][Full Text] [Related]
19. An O-GlcNAcase-specific inhibitor and substrate engineered by the extension of the N-acetyl moiety.
Kim EJ; Perreira M; Thomas CJ; Hanover JA
J Am Chem Soc; 2006 Apr; 128(13):4234-5. PubMed ID: 16568991
[TBL] [Abstract][Full Text] [Related]
20. Cell-penetrant, nanomolar O-GlcNAcase inhibitors selective against lysosomal hexosaminidases.
Dorfmueller HC; Borodkin VS; Schimpl M; Zheng X; Kime R; Read KD; van Aalten DM
Chem Biol; 2010 Nov; 17(11):1250-5. PubMed ID: 21095575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
